Literature DB >> 9877039

Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate.

B Plecko1, W Erwa, B Wermuth.   

Abstract

UNLABELLED: We report on a now 13-year-old girl, who presented with recurrent episodes of vomiting, psychotic behaviour and confusion during puberty until the diagnosis of partial N-acetylglutamate synthetase deficiency was established. She had suffered one prior unclear episode of acute vomiting, lethargy and somnolence at the age of 13 months, and from childhood onward had aversion to high protein food. Treatment with a protein-restricted diet and administration of phenylbutyrate as well as L-arginine were sufficient to normalize ammonia levels but glutamine concentrations remained high. Supplementation with N-carbamylglutamate rapidly improved her protein tolerance and reduced the need for co-medication. To our knowledge, so far only seven patients with N-acetylglutamate synthetase deficiency have been reported.
CONCLUSION: Partial N-carbamylglutamate deficiency has to be considered in the differential diagnosis of hyperammonaemia. If proven by enzyme determination in liver tissue, the disorder should be cautiously treated with N-carbamylglutamate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877039     DOI: 10.1007/s004310050985

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia.

Authors:  Ljubica Caldovic; Hiroki Morizono; Maria Gracia Panglao; Sabrina F Cheng; Seymour Packman; Mendel Tuchman
Journal:  Hum Genet       Date:  2003-02-20       Impact factor: 4.132

Review 2.  Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults.

Authors:  A Cartagena; A N Prasad; C A Rupar; M Strong; M Tuchman; N Ah Mew; C Prasad
Journal:  Can J Neurol Sci       Date:  2013-01       Impact factor: 2.104

3.  Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency.

Authors:  Peter Gessler; Peter Buchal; Hans U Schwenk; Bendicht Wermuth
Journal:  Eur J Pediatr       Date:  2009-06-17       Impact factor: 3.183

4.  Hyperammonaemia as a cause of psychosis in an adolescent.

Authors:  Amaya Bélanger-Quintana; Mercedes Martínez-Pardo; María José García; Bendicht Wermuth; Julián Torres; Esperanza Pallarés; Magdalena Ugarte
Journal:  Eur J Pediatr       Date:  2003-08-27       Impact factor: 3.183

Review 5.  N-acetylglutamate and its changing role through evolution.

Authors:  Ljubica Caldovic; Mendel Tuchman
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

6.  New developments in the treatment of hyperammonemia: emerging use of carglumic acid.

Authors:  Marta Daniotti; Giancarlo la Marca; Patrizio Fiorini; Luca Filippi
Journal:  Int J Gen Med       Date:  2011-01-07

7.  Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency.

Authors:  Johannes Häberle
Journal:  Ther Clin Risk Manag       Date:  2011-08-02       Impact factor: 2.423

8.  N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment.

Authors:  Nicholas Ah Mew; Ljubica Caldovic
Journal:  Appl Clin Genet       Date:  2011-08-24

Review 9.  Drug treatment of inborn errors of metabolism: a systematic review.

Authors:  Majid Alfadhel; Khalid Al-Thihli; Hiba Moubayed; Wafaa Eyaid; Majed Al-Jeraisy
Journal:  Arch Dis Child       Date:  2013-03-26       Impact factor: 3.791

10.  Reduced carbohydrate intake in citrin-deficient subjects.

Authors:  T Saheki; K Kobayashi; M Terashi; T Ohura; Y Yanagawa; Y Okano; T Hattori; H Fujimoto; K Mutoh; Z Kizaki; A Inui
Journal:  J Inherit Metab Dis       Date:  2008-04-14       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.